Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idelalisib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 01 Apr 2021 Results of a post hoc analysis of data pooled from 2 trials (NCT01539512 and NCT01282424) assessing the degree of comorbidity burden and the impact of Idelalisib on bleeding events published in the Leukemia and Lymphoma
    • 21 Jun 2020 Results (N=408), pooled analysis of 4 studies assessing efficacy of Idelalisib in patients with indolent non Hodgkins lymphoma and CLL, presented at the 25th Congress of the European Haematology Association
    • 26 Apr 2019 Results assessing Idelalisib and rituximab for chronic lymphocytic leukaemia in the primary and the extension study, published in the Lancet Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top